Literature DB >> 11145911

The equine herpesvirus 1 UL45 homolog encodes a glycosylated type II transmembrane protein and is involved in virus egress.

D Oettler1, O R Kaaden, A Neubauer.   

Abstract

Experiments to analyze the product of the equine herpesvirus type 1 (EHV-1) UL45 homolog were conducted. Using an antiserum generated against the carboxylterminal 114 amino acids of the EHV-1 UL45 protein, proteins of M(r) 32,000, 40,000, and 43,000 were detected specifically in EHV-1-infected cells. Neither form of the protein was located in purified virions of EHV-1 wild-type strain RacL22 or the modified live vaccine strain RacH, but UL45 was demonstrated to be expressed as a late (gamma-2) protein. Fractionation of infected cells and deglycosylation experiments demonstrated that the EHV-1 UL45 protein represents a type II membrane glycoprotein. Deletion of the UL45 gene in RacL22 and RacH (LDelta45 and HDelta45) showed that UL45 is nonessential for EHV-1 growth in vitro, but that deletion reduced the viruses' replication efficiency. A marked reduction of virus release was observed although no significant influence was noticed either on plaque size or on the syncytial phenotype of the EHV-1 strain RacH. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11145911     DOI: 10.1006/viro.2000.0690

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  2 in total

1.  The equine herpesvirus 1 UL20 product interacts with glycoprotein K and promotes egress of mature particles.

Authors:  Simone Guggemoos; Frank T Just; Antonie Neubauer
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Transcription phase, protein characteristics of DEV UL45 and prokaryotic expression, antibody preparation of the UL45 des-transmembrane domain.

Authors:  Ai-Mei Shen; Guang-Peng Ma; An-Chun Cheng; Ming-Shu Wang; Dan-Dan Luo; Li-Ting Lu; Tao Zhou; De-Kang Zhu; Qi-Hui Luo; Ren-Yong Jia; Zheng-Li Chen; Yi Zhou; Xiao-Yue Chen
Journal:  Virol J       Date:  2010-09-16       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.